These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36959304)

  • 1. DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response.
    Oktay E; Alem F; Hernandez K; Girgis M; Green C; Mathur D; Medintz IL; Narayanan A; Veneziano R
    Commun Biol; 2023 Mar; 6(1):308. PubMed ID: 36959304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
    Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
    Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
    Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
    J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
    Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
    Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants.
    Liu Y; Zhao D; Wang Y; Chen Z; Yang L; Li W; Gong Y; Gan C; Tang J; Zhang T; Tang D; Dong X; Yang Q; Valencia CA; Dai L; Qi S; Dong B; Chow HY; Li Y
    Front Immunol; 2022; 13():1011484. PubMed ID: 36439096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.
    Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Cavazzoni CB; Brook B; Barman S; Chen J; Diray-Arce J; Doss-Gollin S; De Leon M; Prevost-Reilly A; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Sage PT; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
    Sci Transl Med; 2022 Jan; 14(629):eabj5305. PubMed ID: 34783582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
    Li H; Guo L; Zheng H; Li J; Zhao X; Li J; Liang Y; Yang F; Zhao Y; Yang J; Xue M; Zuo Y; Zhou J; Chen Y; Yang Z; Li Y; Jin W; Shi H; He Z; Li Q; Liu L
    Bioconjug Chem; 2021 May; 32(5):1034-1046. PubMed ID: 33951913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
    Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
    Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.
    Kim YI; Kim D; Yu KM; Seo HD; Lee SA; Casel MAB; Jang SG; Kim S; Jung W; Lai CJ; Choi YK; Jung JU
    mBio; 2021 Mar; 12(2):. PubMed ID: 33653891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Liu F; Feng C; Xu S; Wu Q; Tang J; Chen Y; Xu R; Chen F; Gao N; Xu Z; Gu S; Lan Y; Zhou H; Hu X; Wang X
    Vaccine; 2022 Feb; 40(9):1208-1212. PubMed ID: 35094871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity.
    Qu Q; Hao P; Xu W; Li L; Jiang Y; Xu Z; Chen J; Gao Z; Pang Z; Jin N; Li C
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.
    Conforti A; Marra E; Palombo F; Roscilli G; Ravà M; Fumagalli V; Muzi A; Maffei M; Luberto L; Lione L; Salvatori E; Compagnone M; Pinto E; Pavoni E; Bucci F; Vitagliano G; Stoppoloni D; Pacello ML; Cappelletti M; Ferrara FF; D'Acunto E; Chiarini V; Arriga R; Nyska A; Di Lucia P; Marotta D; Bono E; Giustini L; Sala E; Perucchini C; Paterson J; Ryan KA; Challis AR; Matusali G; Colavita F; Caselli G; Criscuolo E; Clementi N; Mancini N; Groß R; Seidel A; Wettstein L; Münch J; Donnici L; Conti M; De Francesco R; Kuka M; Ciliberto G; Castilletti C; Capobianchi MR; Ippolito G; Guidotti LG; Rovati L; Iannacone M; Aurisicchio L
    Mol Ther; 2022 Jan; 30(1):311-326. PubMed ID: 34547465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core.
    Shi R; Zeng J; Xu L; Wang F; Duan X; Wang Y; Wu Z; Yu D; Huang Q; Yao YG; Yan J
    EBioMedicine; 2022 Nov; 85():104297. PubMed ID: 36206623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.